Literature DB >> 19194376

Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study.

Sujung J Yoon1, In Kyoon Lyoo, Charlotte Haws, Tae-Suk Kim, Bruce M Cohen, Perry F Renshaw.   

Abstract

Targeting the glutamatergic system has been suggested as a promising new option for developing treatment strategies for bipolar depression. Cytidine, a pyrimidine, may exert therapeutic effects through a pathway that leads to altered neuronal-glial glutamate cycling. Pyrimidines are also known to exert beneficial effects on cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function, which have each been linked to the pathophysiology of bipolar depression. This study was aimed at determining cytidine's efficacy in bipolar depression and at assessing the longitudinal effects of cytidine on cerebral glutamate/glutamine levels. Thirty-five patients with bipolar depression were randomly assigned to receive the mood-stabilizing drug valproate plus either cytidine or placebo for 12 weeks. Midfrontal cerebral glutamate/glutamine levels were measured using proton magnetic resonance spectroscopy before and after 2, 4, and 12 weeks of oral cytidine administration. Cytidine supplementation was associated with an earlier improvement in depressive symptoms (weeks 1-4; p=0.02, 0.001, 0.002, and 0.004, respectively) and also produced a greater reduction in cerebral glutamate/glutamine levels in patients with bipolar depression (weeks 2, 4, and 12; p=0.004, 0.004, and 0.02, respectively). Cytidine-related glutamate/glutamine decrements correlated with a reduction in depressive symptoms (p=0.001). In contrast, these relationships were not observed in the placebo add-on group. The study results suggest that cytidine supplementation of valproate is associated with an earlier treatment response in bipolar depression. Furthermore, cytidine's efficacy in bipolar depression may be mediated by decreased levels of cerebral glutamate and/or glutamine, consistent with alterations in excitatory neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194376     DOI: 10.1038/npp.2009.2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  23 in total

Review 1.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

3.  Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T.

Authors:  Nivedita Agarwal; Young-Hoon Sung; J Eric Jensen; Grace daCunha; David Harper; David Olson; Perry F Renshaw
Journal:  Bipolar Disord       Date:  2010-12       Impact factor: 6.744

4.  Prospective neurochemical characterization of child offspring of parents with bipolar disorder.

Authors:  Manpreet K Singh; Booil Jo; Nancy E Adleman; Meghan Howe; Layla Bararpour; Ryan G Kelley; Daniel Spielman; Kiki D Chang
Journal:  Psychiatry Res       Date:  2013-09-09       Impact factor: 3.222

Review 5.  Pharmacological treatment of bipolar depression: qualitative systematic review of double-blind randomized clinical trials.

Authors:  Lucas Spanemberg; Raffael Massuda; Lucas Lovato; Leonardo Paim; Edgar Arrua Vares; Neusa Sica da Rocha; Keila Maria Mendes Ceresér
Journal:  Psychiatr Q       Date:  2012-06

6.  Open-label uridine for treatment of depressed adolescents with bipolar disorder.

Authors:  Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Delmastro; Eun-Kee Jeong; Namkug Kim; Xianfeng Shi; Perry F Renshaw
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-12       Impact factor: 2.576

Review 7.  Targeting Mitochondrial Dysfunction for Bipolar Disorder.

Authors:  Maya Kuperberg; Sophie L A Greenebaum; Andrew A Nierenberg
Journal:  Curr Top Behav Neurosci       Date:  2021

8.  Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.

Authors:  Allison C Nugent; Nancy Diazgranados; Paul J Carlson; Lobna Ibrahim; David A Luckenbaugh; Nancy Brutsche; Peter Herscovitch; Wayne C Drevets; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2013-09-18       Impact factor: 6.744

Review 9.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 10.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.